Why We Did What We Did: PSMA PET/CT Selection Criteria for the VISION Trial
Phillip H. Kuo, Taylor L. Benson, Richard A. Messmann, Michael Groaning
Abstract
After years of development and many published studies, prostate-specific membrane antigen–targeted radioligand therapy recently reached a critical milestone on March 23, 2022, with approval of 177Lu-PSMA-617 by the U.S. Food and Drug Administration ([ 1 ][1]). This landmark success heralds a new
Topics & Concepts
MilestoneFood and drug administrationRadioligandProstate cancerSelection (genetic algorithm)MedicinePet imagingDrug developmentMedical physicsInternal medicineOncologyNuclear medicinePositron emission tomographyDrugPharmacologyArtificial intelligenceComputer scienceCancerGeographyCartographyReceptorProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications